Inhibitors of the phosphodiesterase 4 (PDE4) enzyme–like the oral drug roflumilast–have shown a potential to reduce inflammation-mediated processes, and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype [53]. Here, PDE4A is linked to chronic obstructive pulmonary disease.